Tesamorelin Ipamorelin vial — BRAVO1 Wellness

AdvancedGH OptimizationDual-PathwayBody Recomposition

Tesamorelin / Ipamorelin

GHRH + GHRP Dual-Pathway GH Protocol

A precision combination of two complementary GH-axis peptides: Tesamorelin (a GHRH analogue) stimulates the pituitary via the hypothalamic pathway, while Ipamorelin (a selective GHRP) amplifies GH release via the ghrelin receptor — producing a synergistic pulse significantly greater than either alone.

Researched Wellness Applications

✓ Dual-pathway GH & IGF-1 optimization

✓ Visceral fat reduction & body recomposition

✓ Lean muscle preservation & recovery acceleration

✓ Deep sleep enhancement (slow-wave GH pulse)

✓ Longevity, energy & metabolic health support

Assessment Options

$299

No subscription required · Physician reviewed

Start Physician Review →

Physician review required · Ships in 48h after approval · All 50 states

Split payments available with affirm — 0% interest options

What Is It?

Tesamorelin / Ipamorelin explained simply

This protocol pairs two peptides that act on completely separate receptors of the growth hormone axis — creating a compounding effect that neither can achieve alone. Tesamorelin is a stabilized GHRH analogue that binds to the pituitary's GHRH receptors, signaling the release of endogenous GH in a pulsatile, physiologically normal pattern. Ipamorelin is a highly selective growth hormone releasing peptide (GHRP) that binds ghrelin receptors, adding a second, independent GH stimulation signal simultaneously.

The result is a larger, cleaner GH pulse than either peptide generates solo — without meaningfully raising cortisol, prolactin, or other hormones that less selective GHRPs can affect. The combination preserves the body's own negative feedback mechanisms and avoids the receptor downregulation associated with exogenous growth hormone administration.

This dual-pathway protocol is well-regarded in the longevity and performance space for producing noticeable improvements in body composition, recovery speed, sleep depth, and energy — while remaining within the body's natural hormonal architecture.

Complementary GH pathways

GH / IGF-1

Primary axes elevated

Subcutaneous injection

Mechanism

How Tesamorelin / Ipamorelin works

Tesamorelin — GHRH Receptor Activation

Tesamorelin binds to GHRH receptors on pituitary somatotroph cells, triggering synthesis and pulsatile release of endogenous growth hormone. Its stabilized structure gives it a longer active half-life than natural GHRH, with an extensive clinical evidence base including FDA-approved studies on visceral fat reduction. It works with the body's own feedback loop, preventing supraphysiological GH elevation.

Ipamorelin — Ghrelin Receptor Activation

Ipamorelin is a third-generation GHRP with exceptional selectivity. It binds ghrelin receptors in both the pituitary and hypothalamus, stimulating GH release through a completely separate mechanism from GHRH. Critically, Ipamorelin produces minimal impact on cortisol or prolactin — a significant advantage over older GHRPs. Its selective, clean GH pulse makes it the preferred pairing for GHRH-based protocols.

Synergy: Why the Combination Matters

When GHRH and GHRP signals arrive at the pituitary simultaneously, the resulting GH pulse is significantly larger than the additive effect of each alone — a well-characterized synergy in GH physiology. Tesamorelin provides the primary hypothalamic signal; Ipamorelin amplifies and extends it via the ghrelin pathway. The combination also suppresses somatostatin (the GH-inhibiting hormone) more effectively than either alone, creating a longer and more complete GH secretory window.

Administration

Tesamorelin / Ipamorelin is administered via subcutaneous injection, typically once daily in the evening to align with the natural nocturnal GH pulse. Some protocols use twice-daily dosing for enhanced results. The appropriate dosage, frequency, and protocol duration is determined through the BRAVO1 physician review process based on your individual health profile, goals, and baseline labs.

FAQ

Questions about Tesamorelin / Ipamorelin

Both are GHRH + GHRP combinations, but the GHRH component differs. CJC-1295 (with DAC) has an extended half-life of up to 7 days due to its albumin-binding modification, making it suited for less frequent dosing. Tesamorelin has a shorter, more physiological half-life with a stronger evidence base from clinical trials — particularly for visceral fat reduction. The right choice depends on your goals and dosing preference, assessed during physician review.

This combination is typically explored by individuals seeking advanced GH optimization — particularly those focused on body recomposition, longevity, recovery enhancement, or sleep quality improvement. Given it involves two peptides, it is generally recommended for those with prior experience or those who have discussed their goals thoroughly during physician review. Appropriateness is evaluated individually.

Ipamorelin's key advantage is its selectivity — it has been shown to produce minimal increases in cortisol, ACTH, or prolactin compared to older GHRPs like GHRP-2 or GHRP-6. Tesamorelin works through the natural GHRH pathway and is generally well-tolerated. Your reviewing physician will assess your baseline hormone profile before determining suitability.

All BRAVO1 orders ship within 48 hours of physician approval from our temperature-controlled facility. Delivery is available to all 50 states. You'll receive tracking confirmation as soon as your order dispatches.